{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:10:12Z","timestamp":1760001012388,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.jpba.2014.01.006","type":"journal-article","created":{"date-parts":[[2014,1,18]],"date-time":"2014-01-18T16:02:01Z","timestamp":1390060921000},"page":"69-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Performance characteristic of anti-cyclic citrullinated peptide (CCP) assay on Korean rheumatoid arthritis (RA) patients and healthy controls"],"prefix":"10.1016","volume":"92","author":[{"given":"Jae-Chul","family":"Pyun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Hang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyojeong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Youn","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Ok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1398-2037","authenticated-orcid":false,"given":"Min-Jung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2014.01.006_bib0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/ar395","article-title":"Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value","volume":"4","author":"Van Boekel","year":"2002","journal-title":"Arthritis Research"},{"key":"10.1016\/j.jpba.2014.01.006_bib0010","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.jpba.2014.01.006_bib0015","first-page":"10","article-title":"The new ACR\/EULAR classification criteria for RA: how are the new criteria performing in the clinic","volume":"51","author":"Bykerk","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.jpba.2014.01.006_bib0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1172\/JCI1316","article-title":"Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies","volume":"101","author":"Schellekens","year":"1998","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.jpba.2014.01.006_bib0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","article-title":"The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide","volume":"43","author":"Schellekens","year":"2000","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.jpba.2014.01.006_bib0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/ard.60.1.67","article-title":"Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"60","author":"Mediwake","year":"2001","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.jpba.2014.01.006_bib0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.berh.2004.08.005","article-title":"Early diagnosis of rheumatoid arthritis","volume":"19","author":"Visser","year":"2005","journal-title":"Best Practice & Research Clinical Rheumatology"},{"key":"10.1016\/j.jpba.2014.01.006_bib0040","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/ard.2006.051391","article-title":"Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review","volume":"65","author":"Avouac","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.jpba.2014.01.006_bib0045","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1373\/clinchem.2006.078063","article-title":"Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein\/peptide antibodies in the diagnosis of rheumatoid arthritis","volume":"53","author":"Coenen","year":"2007","journal-title":"Clinical Chemistry"},{"key":"10.1016\/j.jpba.2014.01.006_bib0050","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/art.24390","article-title":"Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis","volume":"61","author":"Lopez-Longo","year":"2009","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.jpba.2014.01.006_bib0055","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00296-009-1171-5","article-title":"Diagnostic value of synovial fluid anti-cyclic citrullinated peptide antibody for rheumatoid arthritis","volume":"30","author":"Heidari","year":"2010","journal-title":"Rheumatology International"},{"key":"10.1016\/j.jpba.2014.01.006_bib0060","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.cca.2011.01.013","article-title":"Diagnostic utility of an anti-CCP point-of-care immunotest in Chinese patients with rheumatoid arthritis","volume":"412","author":"Liao","year":"2011","journal-title":"Clinica Chimica Acta"},{"key":"10.1016\/j.jpba.2014.01.006_bib0065","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00296-009-1336-2","article-title":"Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis","volume":"31","author":"Shidara","year":"2011","journal-title":"Rheumatology International"},{"key":"10.1016\/j.jpba.2014.01.006_bib0070","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.clinbiochem.2011.05.021","article-title":"Performance evaluation of Elecsys analysis system for anti-cyclic citrullinated peptide detection in comparison with commercially available ELISA assays in rheumatoid arthritis diagnosis","volume":"44","author":"Cai","year":"2011","journal-title":"Clinical Biochemistry"},{"key":"10.1016\/j.jpba.2014.01.006_bib0075","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s13206-011-5308-8","article-title":"Fluorescence immunoassay of anti-cyclic citrullinated peptide (CCP) autoantibodies by using parylene-H film","volume":"5","author":"Ko","year":"2011","journal-title":"BioChip Journal"},{"key":"10.1016\/j.jpba.2014.01.006_bib0080","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s12257-011-0106-7","article-title":"Immunostick assay for medical diagnosis of rheumatoid arthritis","volume":"16","author":"Ko","year":"2011","journal-title":"Biotechnology and Bioprocess Engineering"},{"key":"10.1016\/j.jpba.2014.01.006_bib0085","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00002281-200405000-00013","article-title":"Rheumatoid factor revisited","volume":"16","author":"Doerner","year":"2004","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1016\/j.jpba.2014.01.006_bib0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.autrev.2006.03.008","article-title":"Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis","volume":"6","author":"Van Venrooij","year":"2006","journal-title":"Autoimmunity Reviews"},{"key":"10.1016\/j.jpba.2014.01.006_bib0095","first-page":"457","article-title":"Diagnostic utility of AxSYM anti-cyclic citrullinated peptide antibody assay","volume":"28","author":"Kim","year":"2008","journal-title":"Korean Journal of Laboratory Medicine"},{"key":"10.1016\/j.jpba.2014.01.006_bib0100","first-page":"1","article-title":"Sensitivity and specificity of anti-cyclic citrullinated peptide antibodies, compared to rheumatoid factor in Syrian rheumatoid arthritis patients","volume":"20","author":"Suheir","year":"2013","journal-title":"International Journal of Pharmaceutical Sciences Review and Research"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708514000132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708514000132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:51:06Z","timestamp":1759999866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708514000132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":20,"alternative-id":["S0731708514000132"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2014.01.006","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Performance characteristic of anti-cyclic citrullinated peptide (CCP) assay on Korean rheumatoid arthritis (RA) patients and healthy controls","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2014.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}